| 标题： | 子宫颈癌PAX1和JAM3双基因甲基化检测流程、报告模板和临床应用的指导性建议专家共识 |
| title： | Expert consensus on the testing process, reporting template and clinical application of PAX1 and JAM3 dual gene methylation detection in cervical cancer |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊断 |
| field： | Diagnosis |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 临床医生、医院及相关单位责执行甲基化检测技术的检验人员 |
| Guide users： | Clinicians, hospitals, and related units are responsible for the inspectors who perform methylation detection technology |
| 证据分级方法： | 牛津循证医学中心（OCEBM）的证据等级 |
| Evidence grading method： | Centre for Evidence-Based Medicine Levels of Evidence |
| 制定单位： | 中国中西医结合学会检验医学专业委员会 中华医学会检验医学分会 中国医师协会检验医师分会 中国妇幼保健协会 中国医疗保健国际交流促进会基层检验技术标准化分会 |
| Formulating unit： | Chinese Association of Integrative Medicine；Chinese Society of Laboratory Medicine；Chinese Laboratory Physician Branch of Chinese Medical Doctor Association；China Maternal and Child Health Association；China International Exchange and Promotive Association for Medical and Health Care |
| 注册时间： | 2024-10-08 |
| Registration time： | |
| 注册编号： | PREPARE-2024CN740 |
| Registration number： | |
| 指南制订的目的： | 子宫颈癌是严重威胁全球女性健康的常见生殖道恶性肿瘤，已成为全球重大公共卫生问题。甲基化检测已经被WHO和多国子宫颈癌筛查指南认为是子宫颈癌新型检测方法，但目前需积累大样本前瞻性研究数据作为指南依据。本专家共识将根据临床研究进展及时进行修订，为检验人员和医生提供PAX1和JAM3双基因甲基化标志物检测流程、报告模板和临床应用的指导性建议，促进子宫颈癌甲基化检测的临床规范化应用，以满足临床应用的需要。并为进一步完善子宫颈癌防治服务体系，努力遏制子宫颈癌发病率、死亡率上升趋势，减轻子宫颈癌疾病负担，进一步完善子宫颈癌防治服务体系，提高综合防治能力，加快我国子宫颈癌的消除进程。 |
| Purpose of the guideline： | Cervical cancer is a common genital malignant tumor that seriously threatens women's health worldwide and has become a major public health problem worldwide. Methylation detection has been recognized as a new detection method for cervical cancer by the WHO and multinational cervical cancer screening guidelines, but it is necessary to accumulate large-sample prospective research data as a guideline basis. This expert consensus will be revised in a timely manner according to the progress of clinical research, and provide testers and doctors with guidance on the detection process, report template and clinical application of PAX1 and JAM3 dual gene methylation markers, so as to promote the clinical standardized application of cervical cancer methylation detection to meet the needs of clinical application. In order to further improve the cervical cancer prevention and treatment service system, strive to curb the rising trend of cervical cancer incidence and mortality, reduce the burden of cervical cancer disease, further improve the cervical cancer prevention and treatment service system, improve the comprehensive prevention and treatment capacity, and accelerate the elimination process of cervical cancer in China. |
